SA
REGN icon

SpiderRock Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

SpiderRock Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Hold
0
– -$25K – 321
2017
Q3 		– Hold
0
– – – 306
2017
Q2 		– Hold
0
– – – 103
2017
Q1 		– Hold
0
– – – 275

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SpiderRock Advisors's REGN Position: Q3 2024 in Review

SpiderRock Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 7.2% in Q3 2024, buying an estimated $279K and bringing the position to 3,758 shares worth $3.95M. The position accounts for 0.06% of the portfolio, ranked #197.

SpiderRock Advisors first reported a position in REGN in Q1 2024 and has held it in 3 quarters since. 1,388 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

  • SpiderRock Advisors held 3,758 shares of Regeneron Pharmaceuticals worth $3.95M as of Q3 2024.
  • SpiderRock Advisors bought 251 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $279K.
  • Regeneron Pharmaceuticals made up 0.06% of SpiderRock Advisors's portfolio in Q3 2024, its #197 holding.
  • SpiderRock Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on SpiderRock Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.